Objective: The likelihood of timely treatment for cervical cancer increases with timely detection of abnormal cervical cells. Automated methods of detecting abnormal cervical cells were established because manual identification requires skilled pathologists and is time consuming and prone to error. The purpose of this systematic review is to evaluate the diagnostic performance of artificial intelligence (AI) technologies for the prediction, screening, and diagnosis of cervical cancer and pre-cancerous lesions. Materials and Methods: Comprehensive searches were performed on three databases: Medline, Web of Science Core Collection (Indexes = SCI-EXPANDED, SSCI, A & HCI Timespan) and Scopus to find papers published until July 2022. Articles that applied any AI technique for the prediction, screening, and diagnosis of cervical cancer were included in the review. No time restriction was applied. Articles were searched, screened, incorporated, and analyzed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results: The primary search yielded 2538 articles. After screening and evaluation of eligibility, 117 studies were incorporated in the review. AI techniques were found to play a significant role in screening systems for pre-cancerous and cancerous cervical lesions. The accuracy of the algorithms in predicting cervical cancer varied from 70% to 100%. AI techniques make a distinction between cancerous and normal Pap smears with 80–100% accuracy. AI is expected to serve as a practical tool for doctors in making accurate clinical diagnoses. The reported sensitivity and specificity of AI in colposcopy for the detection of CIN2+ were 71.9–98.22% and 51.8–96.2%, respectively. Conclusion: The present review highlights the acceptable performance of AI systems in the prediction, screening, or detection of cervical cancer and pre-cancerous lesions, especially when faced with a paucity of specialized centers or medical resources. In combination with human evaluation, AI could serve as a helpful tool in the interpretation of cervical smears or images.

Background: Despite the superiority of minimal access surgery (MAS) over open surgery, MAS is difficult to perform and has a demanding learning curve. Robot-assisted surgery is an advanced form of MAS. The Versius^® surgical robot system was developed with the aim of overcoming some of the challenges associated with existing surgical robots. The present study was designed to investigate the feasibility, clinical safety, and effectiveness of the Versius system in MAS. Materials and Methods: A comprehensive search was carried out in the Medline, Web of Science Core Collection (Indexes = SCI-EXPANDED, SSCI, A & HCI Timespan), and Scopus databases for articles published until February 2022. The keywords used were Versius robot, visceral, colorectal, gynecology, and urologic surgeries. Articles on the use of the Versius robot in minimal access surgery (MAS) were included in the review. Results: Seventeen articles were reviewed for the study. The investigation comprised a total of 328 patients who had been operated on with this robot system, of which 48.3%, 14.2%, and 37.5% underwent colorectal, visceral, and gynecological procedures, respectively. Postoperative and major complications within 30 days varied from 7.4% to 39%. No major complications and no readmissions or reoperations were reported in visceral and gynecological surgeries. Readmission and reoperation rates in colorectal surgeries were 0–9%. Some procedures required conversion to conventional laparoscopic surgery (CLS) or open surgery, and all procedures were completed successfully. Based on the studies reviewed in the present report, we conclude that the Versius robot can be used safely and effectively in MAS. Conclusions: A review of the published literature revealed that the Versius system is safe and effective in minimal access surgery. However, the data should be viewed with caution until randomized controlled trials (RCTs) have been performed. Studies on the use of this robotic system in oncological surgery must include survival as one of the addressed outcomes.

Embryo implantation is one of the most remarkable phenomena in human reproduction and is not yet fully understood. Proper endometrial function as well as a dynamic interaction between the endometrium itself and the blastocyst—the so-called embryo–maternal dialog—are necessary for successful implantation. Several physiological and molecular processes are involved in the success of implantation. This review describes estrogen, progesterone and their receptors, as well as the role of the cytokines interleukin (IL)-6, IL-8, leukemia inhibitory factor (LIF), IL-11, IL-1, and the glycoprotein glycodelin in successful implantation, in cases of recurrent implantation failure (RIF) and in cases of recurrent pregnancy loss (RPL). Are there differences at the molecular level underlying RIF or RPL? Since implantation has already taken place in the case of RPL, it is conceivable that different molecular biological baseline situations underlie the respective problems.

The human microbiome has been given increasing importance in recent years. The establishment of sequencing-based technology has made it possible to identify a large number of bacterial species that were previously beyond the scope of culture-based technologies. Just as microbiome diagnostics has emerged as a major point of focus in science, reproductive medicine has developed into a subject of avid interest, particularly with regard to causal research and treatment options for implantation failure. Thus, the vaginal microbiome is discussed as a factor influencing infertility and a promising target for treatment options. The present review provides an overview of current research concerning the impact of the vaginal microbiome on the outcome of reproductive measures. A non-Lactobacillus-dominated microbiome was shown to be associated with dysbiosis, possibly even bacterial vaginosis. This imbalance has a negative impact on implantation rates in assisted reproductive technologies and may also be responsible for habitual abortions. Screening of the microbiome in conjunction with antibiotic and/or probiotic treatment appears to be one way of improving pregnancy outcomes.

Background: Obstetric violence (OBV), defined as mistreatment or abuse during childbirth, is a pervasive global issue, albeit with regional differences, affecting women's physical and emotional well‐being.Objectives: The purpose of this systematic review and meta‐analysis is to assess the prevalence of OBV to identify risk factors associated with OBV and to make suggestions for improving maternal healthcare practices and policies.Search Strategy: In a systematic review and meta‐analysis, we searched four electronic databases for studies published over 10 years up to 31 January 2024: Medline (PubMed), Scopus, Embase, and Web of Science (WOS). The search was conducted among English language papers using a carefully curated set of keywords.Selection Criteria: We conducted a comprehensive review, including all observational reporting data on the prevalence of and risk factors associated with OBV, irrespective of geographical location. The studies included in the review were required to be published in peer‐reviewed. journals and available in the English language.Data Collection and Analysis: The data of the studies were summarized in an Excel file (version 19) and analyzed using R (version 4.2.3). A meta‐analysis was performed to evaluate the pooled prevalence of and identify risk factors associated with OBV.Main Results: The global prevalence of OBV estimated based on 25 studies, calculated with a random‐effects model, was 59% (95% confidence interval [CI] 0.48–0.70; I² = 99.5%). The most prevalent subdomain of OBV was non‐consented care (37%; 95% CI 0.23–0.50; I² = 99.7%). The following factors were found to be significantly associated with OBV: the presence of a midwife as skilled personnel beside the woman during childbirth (odds ratio [OR] [95% CI] = 0.4 [0.2–0.9]), which might reduce the likelihood of OBV; middle and high levels of income (OR [95% CI] = 0.5 [0.2–0.7]), which might also reduce the likelihood of OBV; and vaginal delivery (OR [95% CI] = 2.08 [1.1–3.08]), which is liable to increase the likelihood of OBV.Conclusion: This systematic review and meta‐analysis highlights the considerable prevalence and multifaceted nature of OBV, underscoring the urgent need for interventions at multiple levels to address this pervasive issue and ensure respectful, safe, and dignified maternal healthcare for all women.

Background and Aim: Endometrial cancer (EC) is the sixth most common cancer among women worldwide. Since global studies are based on awareness of the incidence trend, mortality, geographical diversity, and level of social development and income of countries, this study was conducted to investigate the trend of uterine cancer (UC) in the world in 2019.Methods: Age‐standardized rates (ASR) of incidence, deaths, prevalence, and disability‐adjusted life years (DALYs) of UC, as well as targeted risk factors, were extracted from the Global Burden of Disease (GBD) online database 2019. Pearson correlation coefficient and SPSS 16 were used to calculate the correlation between risk factors and ASR of epidemiological indicators. Statistical significance was considered as p < 0.05.Results: In 2019, the age‐specific incidence and death rate of UC was peaking at 60–64 and 65–69 years, respectively. The highest age‐standardized incidence rate per 100,000 people for UC has been reported in the Northern Mariana Islands, high sociodemographic index (SDI) countries, World Bank High‐Income category, Europe continent and among World Health Organization (WHO) regions were found in the European Region. The highest age‐standardized death rate per 100,000 people for UC has been reported in Grenada, high SDI countries, the World Bank High‐Income category, Europe continent, and among WHO regions found in the European Region. In 2019, the age‐standardized DALYs rate was 53.54 per 100,000 inhabitants, of which 48.49 cases were related to years of life lost (YLLs) and 5.05 cases were related to years lived with disability.Conclusion: According to GBD‐2019, the highest incidence, mortality, and DALY of UC are in Europe. The evidence and traces of diversity can be seen in the inequalities of UC. Race, ethnicity, economic status, level of education and awareness, co‐morbidities, access, grade, and histological type of tumor are the most important causes of this inequality.